Related Research Articles
Harold Eliot Varmus is an American Nobel Prize-winning scientist. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center.
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in the borough of Manhattan in New York City, founded in 1884 as the New York Cancer Hospital. MSKCC is one of 52 National Cancer Institute–designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue, between 67th and 68th streets, in Manhattan.
Arthur D. Levinson is an American businessman and is the current chairman of Apple Inc. (2011–present) and CEO of Calico. He is the former chief executive officer (1995–2009) and chairman (1999–2014) of Genentech.
The Joan & Sanford I. Weill Medical College of Cornell University is Cornell University's biomedical research unit and medical school located in Upper East Side, Manhattan, New York City, New York.
Josep Baselga i Torres, known in Spanish as José Baselga was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein which is impacted in aggressive breast cancers.
Jonathan J. Lewis, M.D., Ph.D., is a surgeon, biomedical researcher and entrepreneur. He was trained in surgery in South Africa, Britain, and the United States, and is a fellow of both the Royal College of Surgeons and the American College of Surgeons. Dr. Lewis was awarded an MB.B.Ch. from University of the Witwatersrand School of Medicine, and his Ph.D. in Molecular Biology from Witwatersrand and Yale School of Medicine. He completed his Surgical Residency at Charlotte Maxeke Johannesburg Academic Hospital and at Yale-New Haven Hospital. Lewis was a Professor of Surgery and Medicine Memorial Sloan-Kettering Cancer Center, before working in the biotechnology and healthcare industries, serving in several CEO and Chairman roles. He is currently chairman and co-founder of the Molecular Ninja Group and chairman and co-founder of Dugri Inc.
Fighting Chance is a United States patient advocate organization that provides counseling for cancer patients and caregivers. Independent from any hospital and funded solely by charitable contributions, Fighting Chance, a 501(c)(3) non-profit, provides free access to hard-to-find resources and professional counseling from the time of diagnosis through treatment to survivorship. Headquartered in Sag Harbor, New York, the organization operates on the East End of Long Island and also offers e-counseling outside the area.
Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.
Peter T. Scardino is an American cancer surgeon, researcher, and author expert in genitourinary and urological cancers particularly cancer of the prostate. He is chair of the Department of Surgery at Memorial Sloan Kettering Cancer Center.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.
Paul Alan Marks was a medical doctor, researcher and administrator. He was a faculty member and president at Memorial Sloan Kettering Cancer Center.
Howard I. Scher is the Chief of the Genitourinary Oncology at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College. He has a depth of experience in clinical trials for novel types of cancer treatment.
Jeffrey Drebin is a surgeon and scientist. He serves as the Department of Surgery Chair at Memorial Sloan Kettering.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
Christine M. Lovly is an associate professor of medicine at Vanderbilt University. Her research involves the development of novel treatment strategies for ALK positive lung cancer.
Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
Levi A. Garraway is an American oncologist. His research team was among the first to adapt genomics technologies to enable scalable, high-throughput clinical approaches to cancer gene mutation profiling. As a result, he was inducted into the American Society for Clinical Investigation, American Association for Cancer Research, and National Academy of Medicine.
Valerie W Rusch, MD, FACS, is an American thoracic surgeon who is currently the Miner Family Chair for Intrathoracic Cancers and Vice Chair for Clinical Research, Department of Surgery, at Memorial Sloan Kettering Cancer Center.
References
- ↑ "BREAKING: Pfizer raids Roche executive committee for new drug development chief — and Schwan plucks his replacement from the board". Endpoints News. Retrieved 1 February 2022.
- 1 2 "William Pao, MD, PhD, Joins Roche to Lead Oncology Research - The ASCO Post". ascopost.com. 15 April 2014. Retrieved 1 February 2022.
- ↑ Pao, W; Miller, V; Zakowski, M; Doherty, J; Politi, K; Sarkaria, I; Singh, B; Heelan, R; Rusch, V; Fulton, L; Mardis, E; Kupfer, D; Wilson, R; Kris, M; Varmus, H (7 September 2004). "EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib". Proceedings of the National Academy of Sciences of the United States of America. 101 (36): 13306–11. Bibcode:2004PNAS..10113306P. doi: 10.1073/pnas.0405220101 . PMC 516528 . PMID 15329413.
- ↑ "William Pao to replace Roche's departing head of pRED". www.thepharmaletter.com.
- ↑ Inc, Biotechnology News Magazine, a division of PTM Healthcare Marketing (1 February 2022). "Pfizer Announces New Chief Development Officer - William Pao, M.D., Ph.D." Biotechnology News Magazine. Retrieved 1 February 2022.
| General | |
|---|---|
| Scientific databases | |
